Imagen de Portada
Código QR

Current Frontline Treatment of Multiple Myeloma.

Treatment paradigms for management of newly diagnosed (ND) multiple myeloma have been evolving over the past 20 years as a consequence of the development of immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. While recent studies have continued to confirm the progression-free s...

Descripción completa

Publicado en:Oncology (08909091) Vol. 36; no. 7; pp. 430 - 442
Autor principal: Holstein, Sarah A.
Formato: review tables/charts Journal Article
Publicado: MJH Life Sciences Jul2022
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=157963589&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 157963589
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        08909091
        YYT
      jtl: Oncology (08909091)
      issn: 08909091
      maglogo: N
    pubinfo:
      dt: Jul2022
      vid: 36
      iid: 7
      pid: 54670
      pub: MJH Life Sciences
      place: Cranbury, New Jersey
    artinfo:
      ui:
        157963589
        157963589
        157963589
        157963589
      ppf: 430
      ppct: 12
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Current Frontline Treatment of Multiple Myeloma.
      aug:
        au: Holstein, Sarah A.
        affil: Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198
      sug:
        subj:
          Multiple Myeloma Therapy
          Literature Review
      ab: Treatment paradigms for management of newly diagnosed (ND) multiple myeloma have been evolving over the past 20 years as a consequence of the development of immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. While recent studies have continued to confirm the progression-free survival benefit of consolidation with upfront autologous stem cell transplant in those considered transplant eligible (TE), the line between induction strategies for TE and transplant-ineligible (TI) patients has blurred, based on studies evaluating both populations. Here, we present an overview of the data guiding current treatment approaches in the ND setting and discuss areas of ongoing investigation, including the role of quadruplet combination therapies in TE patients, the optimal strategies for frail TI patients, and management of high-risk disease.
      pubtype: Academic Journal
      doctype:
        review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N